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Predicted outcomesPurpose: Patient specific quality assurance (PSQA) is required to verify the treatment delivery and the
dose calculation by the treatment planning system (TPS). The objective of this work is to demonstrate
the feasibility to substitute resource consuming measurement based PSQA (PSQAM) by independent dose
recalculations (PSQAIDC), and that PSQAIDC results may be interpreted in a clinically relevant manner
using normal tissue complication probability (NTCP) and tumor control probability (TCP) models.
Methods and materials: A platform for the automatic execution of the two following PSQAIDC workflows
was implemented: (i) using the TPS generated plan and (ii) using treatment delivery log files (log-plan).
30 head and neck cancer (HNC) patients were retrospectively investigated. PSQAM results were compared
with those from the two PSQAIDC workflows. TCP/NTCP variations between PSQAIDC and the initial TPS
dose distributions were investigated. Additionally, for two example patients that showed low passing
PSQAM results, eight error scenarios were simulated and verified via measurements and log-plan based
calculations. For all error scenarios DTCP/NTCP values between the nominal and the log-plan dose were
assessed.
Results: Results of PSQAM and PSQAIDC from both implemented workflows agree within 2.7% in terms of
gamma pass ratios. The verification of simulated error scenarios shows comparable trends between
PSQAM and PSQAIDC. Based on the 30 investigated HNC patients, PSQAIDC observed dose deviations trans-
late into a minor variation in NTCP values. As expected, TCP is critically related to observed dose devia-
tions.
Conclusions: We demonstrated a feasibility to substitute PSQAM with PSQAIDC. In addition, we showed
that PSQAIDC results can be interpreted in clinically more relevant manner, for instance using TCP/NTCP.
 2020 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 150 (2020) 136–141 This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).The preparation of radiotherapy treatments and their delivery is
affected by several sources of uncertainty. Furthermore, radiother-
apy treatments require the acquisition, exchange, storage and pro-
cessing of large amount of digitized data, which can become
corrupted. To ensure that treatments are delivered within clinically
acceptable tolerances, patient specific quality assurance (PSQA)
has always been an essential component of the treatment delivery
process.
Historically, first for 2D, and later 3D conformal radiotherapy,
PSQA was based on independent dose recalculation and in-vivo
dose output measurements. Corresponding recommendations
were for example given in IAEA TRS430 [1], which provided guide-
lines for the implementation of quality assurance (QA) programs in
radiotherapy departments. Within the scope of this study we arefocusing on PSQA aspects, such as, monitor unit (MU), in a broader
sense, dose calculation and delivery check, data transfer and integ-
rity check, but omit such topics as planning process and plan
check.
However, with the introduction of intensity modulated radio-
therapy (IMRT) and later volumetric modulated arc therapy
(VMAT), independent MU recalculations, often performed manu-
ally, became non-feasible due to the complexity of the calculations.
Therefore, upon adoption of IMRT in the clinic, dose calculations
mostly were done by treatment planning systems (TPS). Further-
more, beam modulation required the transfer of large amount of
data to the delivery equipment, which demands complex and pre-
cise functional performance. In order to gain confidence and to ver-
ify the performance of new and relatively non-transparent
automated treatment delivery modalities such as IMRT, in-beam
measurement-based PSQA procedures became an integral part of
QA programs in radiotherapy departments [2], replacing indepen-
Table 1







ES1 0.5 0.5 0
ES2 1.0 1.0 0
ES3 1.0 2.0 0
ES4 0 0 1
ES5 0 0 2.5
ES6 1 2 2.5
ES7 2 2 3
ES8 2 4 5
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procedures have evolved and been addressed by various task
groups, for example, AAPM Task Group No. 218 [3].
Since the introduction of particle therapy in clinical practice,
PSQA has been mainly based on an approach requiring in-beam
measurements (PSQAM). In-beam measurements were a necessity
for passively scattered or uniformly scanned proton treatment
fields in order to perform field calibration on a routine basis, as
TPS was usually providing only relative dose. However, in the
recent years with a wide-spread adoption of pencil beam scanning,
the usefulness and value of continuous PSQAM procedures have
been questioned [4].
Focusing on particle therapy, numerous groups have proposed,
to investigate and implement PSQA procedures that are based on
independent dose recalculation (PSQAIDC), additionally proposing
a use of treatment delivery log files and/or use treatment machine
steering files [5,6] in this process. This topic is of particular interest
for particle therapy centers because of the high cost of treatment
beam time, in which case maximizing clinical throughput allows
treatments to be more accessible to the public. In addition, these
novel methods facilitate the deployment of daily adaptive proton
therapy (PT).
At our institution, we co-developed and implemented an open
source workflow automation platform CAPTAIN [7], on basis of
which we deployed a PSQAIDC procedure that relies on indepen-
dent Monte Carlo (MC) calculations [8] and enables input of treat-
ment delivery log files.
Within the current PSQAIDC process, the evaluation of indepen-
dently recalculated dose distributions is performed using 3D
gamma analysis [9,10] and the assessment of clinical goals, which
are defined and calculated based on dose volume histograms
(DVHs).
The currently deployed PSQAIDC workflow consists of two
stages: (i) an independent dose recalculation based on the treat-
ment plan as received from the TPS (TPS-plan) and (ii) an indepen-
dent dose recalculation based on the treatment plan as
reconstructed from treatment delivery log files (log-plan), which
are obtained from the proton delivery system (PTS) after a dry-
run. Although dry-run requires some beam time, in our practice
so far time required is significantly lower than for a complete
PSQAM procedure (5–7 min vs 30–35 min). The calculations are
performed in the patient geometry. The independence in the
PSQAIDC approach is achieved through an entirely independent
implementation of secondary dose calculation engine from the pri-
mary TPS dose calculation engine. In addition, TPS and IDC uses dif-
ferent material lookup tables for determining elemental
composition related to CT numbers.
In the Netherlands, in accordance with a national consensus, for
most indications patient selection for PT is made following a
model-based approach [11,12]. The underlying principle of the
model-based approach is to select a treatment (protons or pho-
tons) on patient-specific basis that would allow to minimize risk
of therapy induced complications. This is done by calculating nor-
mal tissue complication probability (NTCP) according to approved
models for photon and proton treatment plans with identical tar-
get coverage and determining the difference in NTCP (DNTCP)
between these two plans. If DNTCP is above a certain nationally
agreed threshold, the patient is referred for PT. In the framework
of a Model Based Clinic (MBC), a secondary application of PSQAIDC
could be an additional confirmation of the decision-making pro-
cess underlying patient selection, where NTCP values may be recal-
culated based on QA dose distributions.
The purpose of this study is to further explore PSQA procedures
based on automation and independent dose recalculation
(PSQAIDC) within the unique environment of the MBC. Specifically,
we investigate feasibility to link PSQAIDC with clinically relevantmeasures adopted in the MBC, while also providing means to
enclose model-based patient selection process within the overall
PSQA procedure. In addition, the sensitivity of various indicators
towards delivery errors is evaluated.Methods and materials
A group of 30 consecutive head and neck cancer (HNC) patients
was retrospectively evaluated in this study. For these patients
NTCP values were calculated based on the dose distributions as cal-
culated in the TPS (RayStation 8B, RaySearch, Sweden) by its clin-
ical dose calculation algorithm (Monte Carlo v.4.4). In addition,
both dose distributions (TPS-plan and log-plan) calculated by an
independent MC dose calculation engine (MCsquare) were used
to recalculate NTCP values. MCsquare is an open-source Monte
Carlo proton dose calculation engine [13,14], which utilizes
multi-threaded processing to ensure fast calculation times. Fur-
thermore, PSQAM results were retrieved and compared to PSQAIDC
results in terms of gamma pass ratios. The PSQAM procedure for the
presented cases has been performed at 3 measurement depth
(1 cm and two additional in high dose region varying per field).
The presented gamma pass ratio per patient was calculated as a
ratio between the number of all passing measurement points ver-
sus the total number of measurement points (all fields, all depths
combined).
Additionally, two patients with relatively low gamma pass
ratios as shown in the currently employed nominal PSQAIDC work-
flow were selected. To establish a consistency baseline for log file-
based calculations, treatment delivery log files for 5 clinical frac-
tions were collected and QA doses were calculated using the log-
plan based workflow. Afterwards, for these two patients, multiple
error scenarios (ES) of the nominal plan were created. A python
script to alter spot positions and MU in DICOM ion plans was cre-
ated. It was used to introduce offsets to the prescribed spot posi-
tions and MU for the selected treatment plans. To introduce
errors for each spot, offsets were randomly sampled from normal
distributions. Maximum allowed offsets (2 sigma) were predefined
per ES and are listed in Table 1. In this context, the absolute error is
a fixed offset applied to the whole layer and the relative error is an
offset applied to an individual spot.
Error scenarios 1–6 are designed such that introduced offsets
are within tolerances set in the treatment control system, which
monitors the proton beam delivery online, therefore, such offsets
could in principle appear also in the delivery log files. In contrast,
scenarios 7 and 8 are rather theoretical. If such offsets would occur
during beam delivery, the delivery would be interrupted by the
treatment control system.
For the selected two additional cases (error scenario cases) the
nominal plans and all error scenario plans were delivered by the
PTS, while performing PSQAM procedure with a 2D ionization
chamber array MatriXX PT (IBA Dosimetry, Schwarzenbruck, Ger-
many). The array was positioned at 1 cm depth, in order to capture
138 Dose recalculation based patient specific QAall energy layers within the field. Furthermore, a measurement at
only one depth per field for the error scenarios was done to limit
beam time usage. Each treatment plan consisted of 4 treatment
fields. Measured dose distributions were analyzed using global
2D gamma analysis with 2 mm/2% criteria and a cutoff value of
10%.
Furthermore, log files were collected for these deliveries. Using
the deployed PSQAIDC workflow, independent MC dose calculations
were performed using the log files from the nominal plan and the
error scenarios. Based on these nominal and error scenario doses,
the following quality control parameters were calculated: gamma
pass ratios (criteria 2 mm/2%) and the variations in TCP and NTCP
values.
NTCP values were calculated for grade 2 xerostomia [15,16] and
dysphagia [17,18,19] and for grade 3 tube feeding dependence
[20]. In addition to the risk factors, the probability of xerostomia
in the used model is correlated with the mean dose to the con-
tralateral parotid gland. The probability of dysphagia is correlated
with mean dose to the oral cavity and to the superior pharyngeal
constrictor muscle (PCM), while the probability of tube feeding
dependence is correlated with the mean dose to the superior
PCM, inferior PCM, contralateral parotid gland and cricopharyngeal
muscle.
TCP values were calculated based on the model proposed by
Lühr et al. [21]. Model parameters (tumor control dose D50 and
slope c50) were not calibrated to reflect tumor control probability
in our clinical practice. Values for these parameters were chosen
identical to estimations made by Lühr et al. In the proposed model
TCP correlates with the DVH of the primary gross tumor volume
(GTV), primary clinical tumor volume (CTV) and elective CTV.
TCP values were calculated purely for illustrative purposes.
Results
The results for the measurement based and the two indepen-
dent dose recalculations based PSQA procedures for the first tenFig. 1. Overview of gamma pass ratios (2 mm/2%) for 10 head and neck protonHN patients are shown in Fig. 1. The results include 2D gamma
pass ratios (2 mm/2%) for PSQAM and 3D gamma pass ratios
(2 mm/2%) for independent dose recalculation based on the TPS-
plan and the log-plan. Most of the plans consisted of 4 treatment
fields, with 2 exceptions (pat. 1 and 2), where treatment plans
had 5 fields.
Table 2 summarizes the results for variations in NTCP and TCP
as calculated based on initial TPS dose distributions compared to
recalculated dose distributions based on either the TPS-plan or
the log-plan. Appendix I summarizes the DNTCP data for all 30
patients.
Overall, for the entire 30 patients cohort, averageDNTCP of 0.2%
(SD 0.2%) was observed for dysphagia, when comparing nominal
dose distribution to TPS-plan based QA dose distribution, and
0.1% (SD 0.2%), when comparing to log-plan based QA dose distri-
bution. Average DNTCP of 0.1% (SD 0.3%) was observed for xeros-
tomia, when evaluating TPS-plan QA dose distribution, and 0.1%
(SD 0.3%), in case of log-plan QA dose distribution. While for tube
feeding dependence average DNTCP of 0.0% (SD 0.1%) was
observed for evaluation of TPS-plan QA dose distribution and
0.1% (SD 0.2%) for log-plan QA dose distribution.
The consistency check for the log file-based calculations, as per-
formed using log files from 5 clinical fractions for the 2 error sce-
nario cases, showed SD of 0.1% for gamma pass ratios. In
addition, results from the error scenarios test are shown in Fig. 2.
Results include 2D gamma pass ratios for the measurements per-
formed at 1 cm depth with MatriXX ionization chamber array
and 3D gamma pass ratios for dose recalculated based on treat-
ment delivery log files as collected from deliveries of treatment
plans with introduced offsets to spot positions and prescribed MU.
In Table 3 the effect of introduced errors is reflected in the
changes of NTCP and TCP values for the error scenario cases. The
shown difference in TCP/NTCP is determined by comparing TCP/
NTCP values as calculated for nominal dose distributions and
TCP/NTCP values as calculated for dose distributions, which were
obtained by recalculating log-file based treatment delivery plans.therapy patients. Results are shown for the PSQAM and PSQAIDC procedures.
Table 2
Overview of NTCP and TCP variations between nominal and QA dose distributions for 10 head and neck patients. Variations in NTCP are shown for grade 2 dysphagia and
xerostomia and grade 3 tube feeding dependence at 6 months post radiotherapy.
Pat. TPS-plan dose log-plan dose
DNTCP, % DTCP, % DNTCP, % DTCP, %
Dysph. Xerost. Tube feeding Dysph. Xerost. Tube feeding
1 0.1 0.0 0.0 2.2 0.1 0.1 0.0 3.1
2 0.2 0.0 0.3 1.1 0.3 0.0 0.3 2.1
3 0.2 0,4 0,0 2.0 0,2 0,4 0,0 2.1
4 0.1 0.1 0.1 1.6 0.1 0.0 0.1 1.9
5 0.5 0.3 0.2 1.7 0.0 0.5 0.4 3.0
6 0.1 0.3 0.2 1.4 0.2 0.2 0.3 2.9
7 0.2 0.4 0.0 1.5 0.1 0.1 0.0 2.6
8 0.1 0.5 0.1 2.5 0.2 0.3 0.1 3.3
9 0.2 0.1 0.0 2.1 0.1 0.1 0.0 2.3
10 0.1 0.3 0.2 2.1 0.3 0.5 0.4 3.5
Fig. 2. Trends of gamma pass ratios for 2 error scenario cases, for whom a set of 8 error scenarios was generated and evaluated according to PSQAM and PSQAIDC procedures.
ES0 corresponds to the nominal plan, where no offsets to the prescribed spot positions or MU have been introduced.
Table 3
Overview of TCP and NTCP variations between nominal and QA dose distributions for error scenarios, which were generated for treatment plans of the two HNC patients (error
scenario cases). Scenario ES0 represents PSQAIDC of the unaltered plan.
Patient A Patient B
DNTCP, % DTCP, % DNTCP, % DTCP, %
Dysph. Xerost. Tube feeding Dysph. Xerost. Tube feeding
ES0 0.1 0.5 0.2 2.5 0.2 0.3 0 2.6
ES1 0.3 0.1 0.1 2.6 0.2 0.3 0 1.4
ES2 0.2 1 0.4 1.7 0 0.4 0.1 1.8
ES3 0.1 0.3 0.3 2.3 1 0 0.1 0.3
ES4 0.1 0.4 0.2 2.2 0.3 0.4 0 0.6
ES5 0.2 0.4 0.2 2.3 0.2 0.2 0 1.4
ES6 0.4 0.2 0.1 2.1 0.3 0.6 0 0.8
ES7 0.4 0.1 0.1 3.7 0 0 0 1.4
ES8 0.2 1 0.5 4.0 0.9 0.4 0.1 2.5
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Consistency can be observed between gamma pass ratios
(2 mm/2%) for PSQAM and PSQAIDC as shown by trends in Figs. 1
and 2. Consistent decisions regarding plan quality would be made
according to either PSQAM or PSQAIDC (Fig. 1) and lower gamma
pass ratios would be observed with either method in case of deliv-
ery errors (Fig. 2). In most cases, gamma analysis performed for
measurements done at 3 depths per field scores higher gamma
pass ratios than for independent dose recalculation based PSQA
approach. It is not unexpected that gamma pass ratios between
PSQAM and PSQAIDC will not match, because the two PSQAmethods
have some major fundamental differences, such as the testing
medium. PSQAM is based on water-like medium, while PSQAIDC is
based on patient geometry depicted in the planning CT. Further-more, in PSQAM steep gradient regions, especially in longitudinal
direction, such as distal dose falloff, are often avoided. Gradient
regions would usually score lower gamma pass ratios, if included.
Furthermore, the number of evaluation points in case of PSQAIDC is
much larger, as in case of PSQAM, only a limited number of dose
planes in sampled.
When comparing the two recalculation-based PSQA results, the
log-plan typically scores slightly lower gamma pass ratios than the
TPS-plan. This can be explained by the fact that the log-based plan
also includes delivery discrepancies in spot position and delivered
MU per spot compared to the nominal plan (TPS-plan). In this
sense Patient 6 is an outlier. There were no unusual specifics
noticed in the plan design. This behavior might be explained by
statistical noise in the MC calculations in combination with already
relatively high gamma pass ratios for this case.
140 Dose recalculation based patient specific QAFor all 30 clinical cases plans scored high gamma pass ratios
according to applied PSQA procedures. Therefore, also no major
variations were observed in the NTCP values as calculated for the
three selected complication models. Average observed DNTCP val-
ues were close to zero (0.2% for dysphagia) and the standard devi-
ation remained small (0.3% for xerostomia). By reviewing DNTCP
values in the process of PSQA supplementary to the gamma analy-
sis, one can make better judgement on the clinical relevance of the
observed variations.
Furthermore, by investigating DNTCP values between nominal
and QA dose distributions, it can be ensured that patient selection
for photon or proton therapy, in the context of MBC, is covered
within the PSQA program and decision making is reliable and con-
sistent. In fact, observed maximum variations for discussed 30 clin-
ical cases do not exceed the uncertainty of the NTCP value itself
[15,16] and they are small compared to the clinical decision
thresholds (currently set in the Netherlands at 10% for Common
Terminology Criteria for Adverse Events (CTCAE) grade 2 and 5%
for grade 3 toxicities). Therefore, it may be considered that deci-
sions made regarding patient selection have been robust against
the sources of errors covered by QA process itself.
It should be noted that the used NTCP models are limited to
specific complications and do not cover all possible radiation
induced complications. Furthermore, NTCP models vary greatly in
terms of their quality, availability of validation and may need a
population-specific calibration. In the absence of comprehensive
selection of NTCP models, clinical goals based on DVH statistics
might be employed. For instance, by monitoring mean dose to such
structures as the oral cavity, PCMs, cricopharyngeal muscle and
parotids, one might identify cases when out-of-tolerance devia-
tions occur. For Patient B ES3 (dysphagia DNTCP 1%) mean dose
increase of 1.3 GyRBE to PCM superior and 1.0 GyRBE to oral cavity
was observed. As an example, dose statistics for this case are
shown in Table 4.
The evaluation of eight error scenarios for two exemplary
patient cases revealed consistency of trends for gamma pass ratios
between PSQAM and PSQAIDC procedures. For instance, ES3 for
Patient B shows drop in gamma pass ratio for both QA methods
as can be seen in Fig. 2. Some of the error scenarios (such as,
ES2, ES3, ES8) resulted in larger deviations of NTCP values between
nominal and QA dose distributions, reaching as much as 1% varia-
tions. An example of inconsistency between gamma pass ratio and
clinical implications can be observed in xerostomia DNTCP values
for Patient A. By comparing ES2 and ES8 metrics, one can observe
that gamma pass ratios for these scenarios are 98.7% and 89.4%
respectively (PSQAIDC method), however both scenarios result in
the same 1% increase in probability of xerostomia. These discrep-
ancies may originate from different sources. First, dose deviations
with different signs may cancel out in an organ at risk with no rel-
evant change in the mean OAR dose and the NTCP as a result.
Otherwise, dose deviations may be spatially located outside of
organs at risk as recognized by the used NTCP models. This mayTable 4
Dose statistics for selected organs at risk of exemplary case Patient B. Mean doses are
shown for dose distribution as calculated by TPS, dose distribution as reconstructed








PCM superior 33.5 33.3 34.8
Oral cavity 16.4 16.2 17.4
PCM inferior 40.5 40.2 39.8
Cricopharyngeal m. 16.0 16.5 17.0
Contralateral
parotid
20.0 19.7 20.0be a sign that these dose deviations are not relevant, or, that the
NTCP models are incomplete. Therefore, the use of comprehensive
NTCP profiles that include multiple toxicities and multiple organs
at risk will be paramount for the clinical interpretation of the QA
results. Due to a recent worldwide increase in data registration
programs and implementation of MBCs it is expected that more
and better models for such profiles will emerge in coming years.
In our institution we are working on a comprehensive profile for
HNC patients that includes 22 toxicities at several time points
and describes dose–effect relationships in 14 distinct organs at risk
(preliminary results presented by van den Bosch et al. [22]). Fur-
thermore, as models become more individualized, the dose–effect
relationships may become steeper, allowing increasingly critical
evaluation of dose deviations.
It can be observed that gamma pass ratios in case of PSQAM are
slightly higher than PSQAIDC for the shown 10 clinical cases, while
the opposite behavior can be noticed for error scenario analysis.
This is linked to the fact that measurements were performed at
three depths for the 10 clinical cases, while for error scenario anal-
ysis only one proximal depth of 1 cm was chosen to capture all lay-
ers and be more sensitive to the introduced errors, resulting in
lower gamma pass ratios. Although evaluations at 1 cm depth
might be associated with increased dose calculation uncertainties
due to the dose calculation engine, these effects are more pro-
nounced for analytical engines. Based on the commissioning pro-
cess (average gamma pass ratio 99.6% (SD 0.8%)), the 1 cm depth
has been used as a standard depth of measurement in our clinic
for shallow depth region. Overall a good agreement between TPS
dose and measurements has been observed. To provide a baseline
value, for clinical plans (based on 30 patient cohort) the mean
gamma pass ratio of measurements at 1 cm depth is 99.7% (SD
0.6%).
The used TCP model highly correlates with the DVH of the GTV.
In our case, the independent dose calculation engine systematically
overestimates dose to the target volume by about 1% compared to
the clinical TPS dose calculation engine. Therefore, about 2% TCP
increase for QA doses can be systematically observed (see Table 2).
Furthermore, as mentioned earlier, model parameters were not
calibrated to represent our clinical experience. Nonetheless,
increase in TCP may indicate formation of hot areas (see Table 2,
Pat. A, ES8) and decrease would indicate formation of cold areas
(see Table 2, Pat. B, ES3). In absence of calibrated and reliable
TCP models, one might introduce clinical goals derived from the
DVHs, similarly as was suggested for coping with the lack of NTCP
models. For instance, CTV D2 for Patient A ES8 increased by 2.1
GyRBE, while CTV D98 for Pat. B ES3 decreased by 1.9 GyRBE.
There is a major role for PSQAM procedures during the launch of
a new facility or introduction of a treatment modality or new indi-
cation. However, in long term such procedures cost enormous
amount of beam time, while bringing rather limited added value.
Transition towards adaptive radiotherapy, where adaptations are
performed over increasingly shorter time frames, will make PSQAM
procedures obsolete. If the primary objectives of PSQA are to (i)
verify TPS calculation accuracy (avoiding software bugs in specific
conditions), (ii) verify accuracy of treatment delivery equipment
and (iii) confirm integrity of data during their transfer process, it
might be possible to perform these PSQA tasks with a process that
does not rely on in-beam measurements. For instance, TPS calcula-
tions can be verified by independent dose recalculation, accuracy
of the treatment delivery equipment should be checked during
thorough machine QA procedures, while data transfer integrity
from TPS to PTS and consistency with the prescription can be
checked prospectively by performing analysis of the machine
steering files, while retrospectively the check of treatment delivery
log files can be done. By allowing PTS to translate the plan into
machine steering files as a part of PSQA also partially would allow
A. Meijers et al. / Radiotherapy and Oncology 150 (2020) 136–141 141to check plan deliverability, since in practice it may occur that PTS
is unable to translate a plan into machine steering files. However,
situations, when plan is not deliverable due to technical failures
of the hardware, would not be detected. Eventually, interpreting
QA results in a clinically meaningful manner will facilitate decision
making regarding the quality of the treatment course.
With an availability to retrieve and process daily delivery
related information, such as treatment delivery log files, daily
imaging data [23], etc., in an automated way and being able to link
the outcome of the analysis to clinically meaningful parameters,
such as clinical goals, TCP and NTCP, as one of the possible future
directions for PSQA might be a process that would allow to contin-
uously monitor treatment course and rise warnings, when devia-
tions from physician’s intent occur.
In conclusion, we demonstrated the feasibility to implement a
PSQAIDC procedure that allows to check TPS calculation accuracy,
deliverability and consistency with the prescription, while provid-
ing means to interpret PSQA results in a more clinically relevant
manner by means of TCP/NTCP. As a secondary outcome, MBC
may benefit from the proposed approach, which may be used for
QA of the patient selection process.
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